AQSZF (Aequus Pharmaceuticals) ROE % Adjusted to Book Value: Negative Equity% (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aequus Pharmaceuticals ROE % Adjusted to Book Value?

Aequus Pharmaceuticals AQSZF ROE % Adjusted to Book Value is Negative Equity% as of Sep. 2025. The stock has 6 warning signs investors should review.

Aequus Pharmaceuticals's ROE % for the quarter that ended in Sep. 2025 was Negative Equity. Aequus Pharmaceuticals's PB Ratio for the quarter that ended in Sep. 2025 was N/A. Aequus Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2025 was Negative Equity.

Aequus Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Aequus Pharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Aequus Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aequus Pharmaceuticals ROE % Adjusted to Book Value Chart

Aequus Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -18.73 0.00 0.00 0.00

Aequus Pharmaceuticals Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 Negative Equity

AQSZF vs GCAN, STEK, CBSTQ: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aequus Pharmaceuticals ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Aequus Pharmaceuticals's ROE % Adjusted to Book Value falls into.


Aequus Pharmaceuticals ROE % Adjusted to Book Value Calculation

Aequus Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Aequus Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=Negative Equity / N/A
=Negative Equity

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of Negative Equity% mean?
Aequus Pharmaceuticals (AQSZF) has a ROE % Adjusted to Book Value of Negative Equity% as of Sep. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Aequus Pharmaceuticals and its competitors.
Is Aequus Pharmaceuticals' ROE % Adjusted to Book Value too high?
Aequus Pharmaceuticals' current ROE % Adjusted to Book Value is Negative Equity%.
How does Aequus Pharmaceuticals' ROE % Adjusted to Book Value compare to GCAN and STEK?
Aequus Pharmaceuticals' ROE % Adjusted to Book Value of Negative Equity% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Aequus Pharmaceuticals and its competitors. Aequus Pharmaceuticals's current ROE % Adjusted to Book Value is Negative Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aequus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aequus Pharmaceuticals (AQSZF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 74% below its estimated fair value. The current ROE % Adjusted to Book Value is Negative Equity%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Aequus Pharmaceuticals (AQSZF), the current ROE % Adjusted to Book Value is Negative Equity% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aequus Pharmaceuticals Business Description

Address 200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products namely Tacrolimus IR and Vistitan.